Which of the following medications should a pharmacy technician identify as being included in the Risk Evaluation and Mitigation Strategies (REMS) program?

Isotretinoin, commonly known by its brand name Accutane, is included in the Risk Evaluation and Mitigation Strategies (REMS) program due to its strong potential to cause serious birth defects if taken during pregnancy. The REMS program requires certain safety measures to ensure that patients understand the risks involved with the medication and to reduce the incidence of these risks. This includes measures like mandatory registration with the iPLEDGE program, which ensures that both the healthcare provider and the patient are aware of the teratogenic risks associated with isotretinoin, and that proper contraceptive measures are in place for female patients of childbearing age.

Other medications listed do not have such stringent REMS requirements. Hydrocodone and amphetamines, while controlled substances requiring careful use and monitoring due to the risk of abuse, do not fall under a REMS program specifically focused on mitigating serious birth defects. Alprazolam, although it is a benzodiazepine with risks related to dependence and withdrawal, also does not require REMS. Thus, isotretinoin stands out as the correct medication that is included in a REMS program due to its specific risks.